Lymphoma: all 5,624 studies

Page 15 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell LymphomaCompletedNCT01718691Phase 2Results posted
• A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)CompletedNCT01716806Phase 2Results posted
• Mass Balance, Pharmacokinetics and Metabolism Study of AlisertibCompletedNCT01714947Phase 1Results posted
• A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin LymphomaCompletedNCT01712490Phase 3Results posted
• Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's DiseaseCompletedNCT01702961Not applicableResults posted
• Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT01701986Phase 1/2Results posted
• Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and LymphomaCompletedNCT01700946Phase 2Results posted
• A Study of LY3039478 in Participants With Advanced CancerCompletedNCT01695005Phase 1Results posted
• Safety and Efficacy of BKM120 in Relapsed and Refractory NHLCompletedNCT01693614Phase 2Results posted
• A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT01691898Phase 1/2Results posted
• Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHLCompletedNCT01686165Phase 2Results posted
• Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/LymphomaTerminatedNCT01685606Phase 2Results posted
• Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)CompletedNCT01685008Phase 2Results posted
• Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone LymphomaCompletedNCT01682044Phase 2Results posted
• Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01678443Phase 1Results posted
• Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)CompletedNCT01676831Phase 1/2Results posted
• Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in LymphomaCompletedNCT01665768Phase 2Results posted
• Treatment of Peripheral T-cell LymphomaCompletedNCT01664975Phase 4Results posted
• Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.CompletedNCT01663714Phase 2Results posted
• Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)TerminatedNCT01662102Phase 3Results posted
• Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's LymphomasCompletedNCT01660451Phase 2Results posted
• Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLCompletedNCT01659255Phase 1Results posted
• A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell LymphomaCompletedNCT01649856Phase 3Results posted
• Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyCompletedNCT01646021Phase 3Results posted
• A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase TherapyCompletedNCT01643408Phase 2Results posted
• Everolimus in Treating Cutaneous T-cell LymphomaTerminatedNCT01637090Phase 2Results posted
• KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)CompletedNCT01626664Phase 2Results posted
• Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and LymphomaCompletedNCT01626495Phase 1/2Results posted
• Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP ChemotherapyCompletedNCT01626352Phase 2Results posted
• A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins LymphomaCompletedNCT01614197Phase 1Results posted
• Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TARCompletedNCT01611298Not applicableResults posted
• Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid TissueCompletedNCT01611259Phase 2Results posted
• A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01611090Phase 3Results posted
• A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) LymphomaCompletedNCT01609010Phase 3Results posted
• Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaCompletedNCT01606878Phase 1Results posted
• Double Cord Versus Haploidentical (BMT CTN 1101)CompletedNCT01597778Phase 3Results posted
• A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab TreatmentCompletedNCT01596621Phase 3Results posted
• Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or LymphomaCompletedNCT01593696Phase 1Results posted
• Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant LymphomaCompletedNCT01588548Phase 1Results posted
• PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard TreatmentTerminatedNCT01581541Phase 1Results posted
• Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous LymphomaTerminatedNCT01579318Phase 2Results posted
• Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin LymphomaCompletedNCT01578967Not applicableResults posted
• A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01578707Phase 3Results posted
• A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)CompletedNCT01578499Phase 3Results posted
• Maintenance Lenalidomide in LymphomaCompletedNCT01575860Phase 1/2Results posted
• A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)CompletedNCT01573000Phase 2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Collecting and Studying Tissue Samples From Patients With HIV-Associated MalignanciesTerminatedNCT01567722Results posted
• Rasburicase and Allopurinol in Treating Patients With Hematologic MalignanciesTerminatedNCT01564277Phase 2Results posted
• A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma PatientsCompletedNCT01561833Phase 1Results posted
• Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01555541Phase 2Results posted
• Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's LymphomaTerminatedNCT01549886Phase 2Results posted
• Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for LymphomaCompletedNCT01538472Phase 1/2Results posted
• Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's LymphomaCompletedNCT01536561Phase 1Results posted
• Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT01535924Phase 1/2Results posted
• Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin LymphomaCompletedNCT01534078Phase 2Results posted
• A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched RelativesTerminatedNCT01532635Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT01527149Phase 2Results posted
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01527045Phase 2Results posted
• Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCTCompletedNCT01523834Phase 2Results posted
• Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsCompletedNCT01520519Phase 2Results posted
• Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaCompletedNCT01515176Phase 1/2Results posted
• A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasCompletedNCT01512758Phase 1Results posted
• Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell LymphomaCompletedNCT01511562Phase 2Results posted
• Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyTerminatedNCT01510184Phase 3Results posted
• Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT01500083Phase 3Results posted
• Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood CancerCompletedNCT01499303Phase 2Results posted
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesCompletedNCT01499147Not applicableResults posted
• Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT01497496Phase 2Results posted
• Zevalin and Velcade in Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01497275Phase 2Results posted
• Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLLCompletedNCT01496976Phase 2Results posted
• Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaCompletedNCT01492088Phase 1/2Results posted
• IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's LymphomaCompletedNCT01491841Phase 1Results posted
• Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)CompletedNCT01490723Phase 2Results posted
• A Study of the HSP90 Inhibitor AUY922TerminatedNCT01485536Phase 2Results posted
• Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaCompletedNCT01482962Phase 3Results posted
• Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT01481129Phase 2Results posted
• Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaCompletedNCT01476787Phase 3Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
• Lenalidomide Plus Rituxan for Untreated Mantle Cell LymphomaCompletedNCT01472562Phase 2Results posted
• Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's LymphomaTerminatedNCT01468311Phase 1/2Results posted
• Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin LymphomaCompletedNCT01466881Phase 2Results posted
• A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous RituximabCompletedNCT01461928Phase 3Results posted
• A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT01460940Phase 2Results posted
• Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and EtoposideCompletedNCT01458366Phase 1/2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin DiseaseCompletedNCT01458288Phase 2Results posted
• A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01456039Phase 1/2Results posted
• Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or LymphomaCompletedNCT01454076Phase 1Results posted
• A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01453205Phase 2Results posted
• NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic LymphomaCompletedNCT01451515Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)CompletedNCT01449461Phase 1/2Results posted
• Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasCompletedNCT01445535Phase 1Results posted
• High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaTerminatedNCT01434472Phase 2Results posted
• Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT01433731Phase 1Results posted
• A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or LymphomaCompletedNCT01432951Phase 1Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01421667Phase 2Results posted
• Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma PatientsTerminatedNCT01420679Phase 3Results posted
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2Results posted

← Lymphoma overview